[Antithrombotic therapy in acute myocardial infarct]

Area of Science:

• Cardiology
• Pharmacology
• Thrombosis Research

Context:

• Acute coronary syndromes (ACS) are primarily caused by thrombotic occlusion of coronary arteries.
• Antiplatelet therapy plays a significant role in the prevention and treatment of ACS.
• Anticoagulation, particularly with heparin, is also justified in ACS management.

Purpose:

• To review the current therapeutic strategies for managing coronary artery thrombosis and acute coronary syndromes.
• To evaluate the role of various anticoagulants, including heparin, coumarin derivatives, and newer agents, in ACS treatment.
• To discuss the comparative efficacy and risks of different antithrombotic therapies.

Summary:

• Antiplatelet therapy is a cornerstone in managing acute coronary syndromes (ACS) due to coronary artery thrombosis.
• Heparin and its derivatives are essential adjuncts, especially with thrombolytics like alteplase (t-PA).
• While oral anticoagulants like coumarin derivatives have specific indications (e.g., atrial fibrillation), antiplatelet therapy is often preferred for ACS due to bleeding risks. Emerging therapies include direct thrombin inhibitors and glycoprotein IIb/IIIa antagonists.
• Ongoing research explores low-molecular-weight heparin and comparisons between low-dose aspirin and coumarin derivatives.

Impact:

• Provides a comprehensive overview of antithrombotic strategies for ACS.
• Highlights the evolving landscape of anticoagulant and antiplatelet therapies.
• Informs clinical decision-making regarding the optimal use of anticoagulants and antiplatelet agents in patients with coronary ischaemia.